二甲基-丁酸酰肼 | 1016226-24-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 二甲基-丁酸酰肼
• 英文名称: Dimethyl-butyric acid hydrazide
• 英文别名: 2,2-dimethylbutanehydrazide
• CAS: 1016226-24-6
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: NIIGLPLCEWVSRS-UHFFFAOYSA-N

物化性质

• 沸点：
  256.2±9.0 °C(Predicted)
• 密度：
  0.948±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二甲基-丁酸酰肼 、 5-(2-methoxy-3,4,5,6-tetrahydropyridin-4-yl)-3-phenyl-1,2,4-oxadiazole 在 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 5-[3-(1,1-dimethylpropyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-7-yl]-3-phenyl-1,2,4-oxadiazole
  参考文献：
  名称：

  [EN] TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA
  [FR] COMPOSÉS DE TÉTRAHYDROTRIAZOLOPYRIDINE EN TANT QUE POTENTIALISATEURS SÉLECTIFS DE RÉCEPTEUR MGLU5 UTILES POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE

  摘要：

  本发明提供了某些四氢三唑吡啶衍生物，其药物组合物，使用方法以及制备方法。其中，化学式（I）中R1为氢、氟、氯或甲基；R2为C4 - CS支链烷基。

  公开号：

  WO2011082010A1
• 作为产物：
  描述：

  2,2-二甲基丁酸 在 盐酸 、 一水合肼 作用下， 反应 77.0h， 生成 二甲基-丁酸酰肼
  参考文献：
  名称：

  [EN] TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA
  [FR] COMPOSÉS DE TÉTRAHYDROTRIAZOLOPYRIDINE EN TANT QUE POTENTIALISATEURS SÉLECTIFS DE RÉCEPTEUR MGLU5 UTILES POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE

  摘要：

  本发明提供了某些四氢三唑吡啶衍生物，其药物组合物，使用方法以及制备方法。其中，化学式（I）中R1为氢、氟、氯或甲基；R2为C4 - CS支链烷基。

  公开号：

  WO2011082010A1

文献信息

• TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE
  申请人：Bristol-Myers Squibb Company

  公开号：US20160130299A1

  公开（公告）日：2016-05-12

  Tubulysin analogs of the formula (I) where R 1 , R 2 R 3 , R 4 , R 5 , R 6 , R 7 , and Y are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.

  管素类似物公式(I)，其中R1、R2、R3、R4、R5、R6、R7和Y如本文所述定义，是一种抗有丝分裂剂，可用于癌症治疗，特别是在与靶向部分结合时。
• 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
  申请人：Patel Mahesh Vithalbhai

  公开号：US20140148431A1

  公开（公告）日：2014-05-29

  Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed.

  公式（I）的化合物，其制备和在预防或治疗细菌感染中的应用被披露。
• Methods of treating diseases and disorders by targeting multiple kinases
  申请人：Narla Rama Krishna

  公开号：US20050107386A1

  公开（公告）日：2005-05-19

  The present invention is directed to the use of single agents, which are compounds that target two or more kinases simultaneously, thus substantially avoiding resistance to therapy. The invention provides methods for the use for, administration to, and treatment of individuals having a variety of diseases or conditions associated with the activity of two or more kinases, comprising administration of one or more single agents, either alone or in combination with other therapies for the same disease or condition.

  本发明涉及使用单一药剂，这些药剂是同时靶向两个或更多激酶的化合物，从而大大避免对治疗的抵抗。该发明提供了用于治疗与两个或更多激酶活性相关的各种疾病或病况的方法，包括给予一个或多个单一药剂的给药、管理和治疗，可以单独使用，也可以与其他治疗同一疾病或病况的疗法结合使用。
• Indazole compounds and methods of use thereof
  申请人：Bhagwat S. Shripad

  公开号：US20060004043A1

  公开（公告）日：2006-01-05

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Bhagwat Shripad S.

  公开号：US20090099178A1

  公开（公告）日：2009-04-16

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防许多对激酶的抑制、调节或调控具有反应性的疾病和障碍方面具有用途，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病相关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还揭示了治疗或预防这些疾病和障碍的方法，以及包含一种或多种吲唑化合物的制药组合物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，这些分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和经肠道给药的活性分子，可用于治疗与蛋白激酶信号转导相关的疾病或障碍，且可用较低剂量或血清浓度。